Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals

OBJECTIVES: Recent safety concerns regarding gadolinium-based contrast agents (GdCAs) concluded with the suspension of some agents from the European market, yet a clinical consequence remains unknown. We used electronic health records to investigate the incidence of potential toxicity to gadoteric a...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Laura K., Matthew, Shona Z., Houston, J. Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Contrast Media
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420614/
https://www.ncbi.nlm.nih.gov/pubmed/30276674
http://dx.doi.org/10.1007/s00330-018-5737-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420614/
https://www.ncbi.nlm.nih.gov/pubmed/30276674
http://dx.doi.org/10.1007/s00330-018-5737-z

Ejemplares similares